co.don AG Logo

co.don AG

Develops personalized cartilage cell transplants for minimally invasive joint repair.

CNW | F

Overview

Corporate Details

ISIN(s):
DE000A3E5C08 (+1 more)
LEI:
3912006R73YW0SX1KG21
Country:
Germany
Address:
Warthestr. 21, 14513 Teltow
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

co.don AG is a biopharmaceutical company specializing in tissue engineering and regenerative medicine. The company focuses on the development, manufacturing, and marketing of autologous cell therapies for the treatment of articular cartilage defects. Its core process involves using a patient's own cartilage cells (chondrocytes) to produce personalized cell transplants, such as spherical cartilage cell implants (spheroids), for the minimally invasive repair of joints. Following an asset purchase in early 2023, the operative business was taken over by an investor and now operates as CO.DON GmbH, a ReLive company, continuing its work in human cell-based therapies.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2022-09-30 00:00
Interim Report
Halbjahresfinanzbericht nach WpHG zum Geschäftsjahr vom 01.01.2022 bis zum 30.0…
German 142.4 KB
2022-09-29 00:00
Report Publication Announcement
Hinweis auf Halbjahresfinanzbericht vom 01.01.2022 bis zum 30.06.2022
German 6.4 KB
2022-07-11 00:00
Regulatory News Service
Jahres- und Konzernabschluss zum Geschäftsjahr vom 01.01.2021 bis zum 31.12.2021
German 1.3 MB
2022-07-06 00:00
Report Publication Announcement
Berichtigung der Veröffentlichung vom 14.06.2022
German 6.4 KB
2022-06-14 00:00
Report Publication Announcement
Berichtigt am 06.07.2022
German 6.4 KB
2022-04-29 00:00
Report Publication Announcement
Hinweis auf Jahresfinanzbericht vom 01.01.2021 bis zum 31.12.2021
German 6.4 KB
2021-09-11 00:00
Director's Dealing
CO.DON AG: Mitteilung über Eigengeschäfte von Führungskräften gem. Art. 19 MAR
German 13.9 KB
2021-08-30 00:00
Interim Report
Halbjahresfinanzbericht
German 148.6 KB
2021-05-27 00:00
Report Publication Announcement
Jahresabschluss zum Geschäftsjahr vom 01.01.2020 bis zum 31.12.2020
German 4.2 KB
2021-05-25 00:00
Annual Report
Konzernabschluss zum Geschäftsjahr vom 01.01.2020 bis zum 31.12.2020
German 4.2 KB
2021-05-22 00:00
Regulatory News Service
Ad-hoc-Meldung gemäß Art. 17 MAR in Verbindung mit § 4 Abs. 1 S. 1 Nr. 1a WpAV
English 11.8 KB
2020-08-28 00:00
Interim Report
Datum:28.08.2020
German 381.2 KB
2020-08-24 00:00
Report Publication Announcement
Datum:24.08.2020
German 12.2 KB
2020-07-28 00:00
Annual Report
Datum:28.07.2020
German 998.8 KB
2020-07-07 00:00
Annual Report
Datum:07.07.2020
German 41.3 KB

Automate Your Workflow. Get a real-time feed of all co.don AG filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for co.don AG

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for co.don AG via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
2021-10-21 Günther, Bernd Supervisory board Buy None 35.84 EUR
2021-10-20 Laik, Robin Board Other None 10,348,300.00 EUR
2021-10-20 ELBER GmbH Close relation Other None 10,179,000.00 EUR
2021-10-20 Rofalski, Volker Supervisory board Other None 292,500.00 EUR
2021-10-20 Müller, Dr. Axel Supervisory board Other None 195,000.00 EUR
2021-10-20 Laumann, Johannes Board Other None 131,625.00 EUR
2021-10-20 Laik, Louisa Close relation Other None 129,987.00 EUR
2021-10-20 Laik, Daniel Close relation Other None 97,500.00 EUR
2021-10-20 Friedrich, Neela Close relation Other None 64,993.50 EUR
2021-10-20 Schleede, Dr. Kristian Board Other None 29,250.00 EUR

Peer Companies

Olema Pharmaceuticals, Inc. Logo
A clinical-stage biopharma developing targeted therapies for women's cancers, focusing on breast cancer.
United States of America
OLMA
OliX Pharmaceuticals, Inc. Logo
Developing RNAi therapeutics for dermatology, ophthalmology, and metabolic diseases via an asiRNA platform.
South Korea
226950
OMEROS CORP Logo
Develops first-in-class therapeutics for challenging diseases with unmet medical needs.
United States of America
OMER
ONCODESIGN Logo
Developing precision oncology solutions for resistant and metastatic cancers.
France
ALONC
Oncodesign Precision Medicine S.A Logo
Develops precision therapies & diagnostics for resistant and metastatic cancers.
France
ALOPM
Oncoinvent ASA Logo
Developing alpha-emitting radiotherapies for treating cancers in the peritoneal cavity.
Norway
OCIN
Oncolys BioPharma Inc. Logo
Developing oncolytic virus therapies and diagnostics for cancer and serious viral infections.
Japan
4588
ONCOLYTICS BIOTECH INC Logo
Developing an immuno-oncolytic virus to treat breast and gastrointestinal cancers.
United States of America
ONCY
Onconetix, Inc. Logo
Develops diagnostics and therapeutics for men's health and oncology markets.
United States of America
ONCO
Oncopeptides Logo
Develops targeted therapies for hematological cancers using peptide-drug conjugate technology.
Sweden
ONCO

Talk to a Data Expert

Have a question? We'll get back to you promptly.